vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
Enhabit, Inc. is the larger business by last-quarter revenue ($270.4M vs $263.6M, roughly 1.0× BALCHEM CORP). BALCHEM CORP runs the higher net margin — 14.9% vs -14.3%, a 29.2% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (9.8% vs 4.7%). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (4.9% CAGR vs 1.5%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
BCPC vs EHAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $270.4M |
| Net Profit | $39.2M | $-38.7M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | -12.3% |
| Net Margin | 14.9% | -14.3% |
| Revenue YoY | 9.8% | 4.7% |
| Net Profit YoY | 16.8% | 15.9% |
| EPS (diluted) | $1.21 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $270.4M | ||
| Q3 25 | $267.6M | $263.6M | ||
| Q2 25 | $255.5M | $266.1M | ||
| Q1 25 | $250.5M | $259.9M | ||
| Q4 24 | $240.0M | $258.2M | ||
| Q3 24 | $239.9M | $253.6M | ||
| Q2 24 | $234.1M | $260.6M | ||
| Q1 24 | $239.7M | $262.4M |
| Q4 25 | $39.2M | $-38.7M | ||
| Q3 25 | $40.3M | $11.1M | ||
| Q2 25 | $38.3M | $5.2M | ||
| Q1 25 | $37.1M | $17.8M | ||
| Q4 24 | $33.6M | $-46.0M | ||
| Q3 24 | $33.8M | $-110.2M | ||
| Q2 24 | $32.1M | $-200.0K | ||
| Q1 24 | $29.0M | $200.0K |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | -12.3% | ||
| Q3 25 | 20.4% | 6.4% | ||
| Q2 25 | 20.1% | 6.3% | ||
| Q1 25 | 20.4% | 6.1% | ||
| Q4 24 | 19.8% | -16.0% | ||
| Q3 24 | 20.0% | -38.6% | ||
| Q2 24 | 19.6% | 4.3% | ||
| Q1 24 | 17.4% | 4.9% |
| Q4 25 | 14.9% | -14.3% | ||
| Q3 25 | 15.1% | 4.2% | ||
| Q2 25 | 15.0% | 2.0% | ||
| Q1 25 | 14.8% | 6.8% | ||
| Q4 24 | 14.0% | -17.8% | ||
| Q3 24 | 14.1% | -43.5% | ||
| Q2 24 | 13.7% | -0.1% | ||
| Q1 24 | 12.1% | 0.1% |
| Q4 25 | $1.21 | $-0.76 | ||
| Q3 25 | $1.24 | $0.22 | ||
| Q2 25 | $1.17 | $0.10 | ||
| Q1 25 | $1.13 | $0.35 | ||
| Q4 24 | $1.03 | $-0.92 | ||
| Q3 24 | $1.03 | $-2.20 | ||
| Q2 24 | $0.98 | $0.00 | ||
| Q1 24 | $0.89 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $43.6M |
| Total DebtLower is stronger | — | $426.0M |
| Stockholders' EquityBook value | $1.3B | $534.0M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $43.6M | ||
| Q3 25 | $65.1M | $56.9M | ||
| Q2 25 | $65.4M | $37.1M | ||
| Q1 25 | $49.9M | $39.5M | ||
| Q4 24 | $49.5M | $28.4M | ||
| Q3 24 | $73.7M | $45.7M | ||
| Q2 24 | $63.7M | $28.5M | ||
| Q1 24 | $60.3M | $36.5M |
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $441.5M | ||
| Q2 25 | — | $456.9M | ||
| Q1 25 | — | $467.3M | ||
| Q4 24 | — | $492.6M | ||
| Q3 24 | — | $502.9M | ||
| Q2 24 | — | $512.7M | ||
| Q1 24 | — | $526.7M |
| Q4 25 | $1.3B | $534.0M | ||
| Q3 25 | $1.3B | $566.8M | ||
| Q2 25 | $1.3B | $552.4M | ||
| Q1 25 | $1.2B | $543.2M | ||
| Q4 24 | $1.1B | $523.5M | ||
| Q3 24 | $1.2B | $566.1M | ||
| Q2 24 | $1.1B | $674.3M | ||
| Q1 24 | $1.1B | $672.3M |
| Q4 25 | $1.7B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.4B | ||
| Q1 24 | $1.6B | $1.4B |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $4.4M |
| Free Cash FlowOCF − Capex | — | $3.3M |
| FCF MarginFCF / Revenue | — | 1.2% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $4.4M | ||
| Q3 25 | $65.6M | $37.8M | ||
| Q2 25 | $47.3M | $10.6M | ||
| Q1 25 | $36.5M | $17.9M | ||
| Q4 24 | $52.3M | $-4.1M | ||
| Q3 24 | $51.3M | $28.4M | ||
| Q2 24 | $45.0M | $9.6M | ||
| Q1 24 | $33.4M | $17.3M |
| Q4 25 | — | $3.3M | ||
| Q3 25 | — | $36.2M | ||
| Q2 25 | — | $8.7M | ||
| Q1 25 | — | $17.6M | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $8.9M | ||
| Q1 24 | — | $15.5M |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -1.8% | ||
| Q3 24 | — | 10.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | 5.9% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | 3.41× | ||
| Q2 25 | 1.23× | 2.04× | ||
| Q1 25 | 0.98× | 1.01× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | 86.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
